The funding will enable Aspect to propel multiple bioprinted tissue therapeutic projects toward clinical trials. Credit: luchschenF/Shutterstock.

Aspect Biosystems has secured $115m in a Series B financing round to advance the development of bioprinted tissue therapeutics.

Multistage investment company Dimension spearheaded the financing round, which saw contributions from a mix of existing and new investors including Novo Nordisk, Pallasite Ventures and T1D Fund.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The proceeds from the Series B funding round will enable Aspect to propel multiple bioprinted tissue therapeutic projects toward clinical trials.

The company plans to create a new category of cellular medicines that can offer functional cures for individuals suffering from serious metabolic and endocrine ailments.

Aspect Biosystems founder and CEO Tamer Mohamed stated: “I am incredibly proud of the progress our team is making on our mission to develop disease-modifying treatments for people living with serious diseases.

“We are thrilled to partner with Dimension and this exceptional, mission-aligned investor syndicate.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The investment will support the expansion of Aspect’s full-stack tissue therapeutic platform.

The platform is distinctive for its integration of AI-powered bioprinting technology, computational design tools, advanced biomaterials and therapeutic cells.

Dimension’s founder and managing partner Nan Li joined the board of directors of Aspect, concurrent with the financing.

Li said: “The company brings together capabilities across tissue engineering, cell therapy, biomaterials, computer vision and robotics to deliver on the promise of regenerative medicine. We are beyond excited to partner with the Aspect team to advance their programs forward and to build a generational company.” 

This financial boost follows Aspect’s recent progress, which includes a C$200m collaboration with the Canadian and British Columbian governments.